GSK PLC (NYSE:GSK)
$ 34.08 -0.04 (-0.12%) Market Cap: 69.61 Bil Enterprise Value: 84.95 Bil PE Ratio: 21.96 PB Ratio: 3.90 GF Score: 71/100

GSK plc -Getting Ahead of Respiratory Diseases Transcript

Nov 30, 2023 / 01:00PM GMT
Release Date Price: $35.99 (+1.41%)
Unidentified Company Representative

Hello, everyone. Welcome to our Getting ahead of Respiratory Diseases event with GSK management. As usual, the presentation was e-mailed to our distribution list earlier today and is available on gsk.com. Please turn to Slide 2. This is the usual cautionary and forward-looking statements. Please turn to Slide 3. Today's speakers are our Chief Scientific Officer, Tony Wood; and Chief Commercial Officer, Luke Miels. And our presentation will last approximately 30 minutes a day followed by 30 minutes for Q&A. Turning to Slide 4. I will now hand the call over to Tony.

Tony Wood
GSK plc - Chief Scientific Officer

Hi, everyone, and welcome to our Respiratory Meet the Management event. As you know, GSK prevents and treats disease in 4 therapy areas. Most recently, we spoke to you about HIV. Today, we'll focus on respiratory, where we have assets across vaccines, specialty and general medicines product areas.

Please turn to the next slide. In this deep dive, we'll cover the following areas: firstly, our expertise in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot